ARWR (Arrowhead Pharmaceuticals) FFO


ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $79.81
GF Value $52.23
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $79.81 is trading 52.8% above its estimated GF Value™ of $52.23. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • FFO:
  • GF Value™: $52.23 vs. price of $79.81 (52.8% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.81
Price
$52.23
GF Value